IDEXX Laboratories Announces Fourth Quarter and Full Year 2025 Results

WESTBROOK, Maine--( BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced fourth quarter and full year results.

Fourth Quarter and Full Year Results

The Company reports revenues of $1,091 million for the fourth quarter of 2025, an increase of 14% compared to the prior year period as reported and 12% on an organic basis, driven by Companion Animal Group ("CAG") growth of 15% as reported and 13% organic and Water revenue growth of 12% as reported and 10% organic.

Earnings per diluted share (“EPS”) were $3.08 for the fourth quarter, an increase of 18% as reported and 17% on a comparable basis. Results reflect operating margin expansion of 150 basis points as reported and 120 basis points on a comparable basis. Fourth quarter EPS included $0.09 per share positive impact from currency changes and $0.07 per share in tax benefits from share-based compensation.

Revenue for the full year of $4,304 million increased 10% as reported and organically, driven by 9% as reported and 8% organic growth in CAG Diagnostics recurring revenue.

For the full year 2025, EPS of $13.08 increased 23% on a reported basis and 14% on a comparable basis, including a ~7% EPS growth benefit from comparison to the prior years discrete litigation expense accrual. EPS results reflect operating margin expansion of 270 basis points as reported, including a ~180 basis point positive impact from comparison to the prior years discrete litigation expense accrual, and 90 basis points on a comparable basis. EPS results include lapping a $0.56 negative impact in 2024 and an $0.08 positive impact in the first quarter of 2025 from a discrete litigation expense accrual adjustment, as well as $0.35 in tax benefits from share-based compensation, and $0.10 positive impact from currency changes.

“IDEXX delivered a strong finish to 2025, supported by consistently high levels of execution by IDEXX teams around the world,” said Jay Mazelsky, President and Chief Executive Officer. “2025 was a pivotal year for the Company, marked by the successful launch of IDEXX Cancer Dx™ for canine lymphoma and meaningful adoption of IDEXX inVue Dx well ahead of our initial goals. These innovations represent an important new phase of IDEXX’s growth, expanding the role of diagnostics in earlier disease detection while helping veterinarians improve efficiency and manage workflow complexity. We enter 2026 with an exciting innovation pipeline, expanding instrument and software installed bases, and strong momentum across our global business.”

Fourth Quarter Performance Highlights

Companion Animal Group

CAG revenue growth was led by CAG Diagnostics recurring revenue growth of 12% as reported and 10% organic, including 17% reported and 12% organic gains in international regions, and 9% reported and organic growth in the U.S., outpacing sector growth levels. U.S. growth was aided by increased diagnostic frequency, including early benefits from an aging pet population.

Additional U.S. companion animal practice key metrics are available in the Q4 2025 Earnings Snapshot accessible on the IDEXX website, www.idexx.com/investors.

Sustained commercial execution - including net customer gains, growing benefits from IDEXX innovation, and expansion of the premium instrument installed base - drove double-digit CAG Diagnostics recurring revenue growth.

CAG Diagnostics capital instrument revenues expanded 76% as reported and 69% on an organic basis, led by record quarterly instrument placements, including benefits from over 1,900 IDEXX inVue Dx placements and nearly 1,400 new and competitive Catalyst placements.

Veterinary software, services and diagnostic imaging systems revenue growth increased 13% as reported and organically, led by continued cloud-native software installed base expansion.

Water

Water revenues grew 12% reported and 10% organic for the quarter, reflecting solid growth in the U.S. and International regions.

Livestock, Poultry and Dairy (“LPD”)

LPD revenues increased 8% reported and 4% organic for the quarter, led by solid gains in North and Latin America across major product categories.

Gross Profit and Operating Profit

Gross profit increased 15% as reported and 13% on a comparable basis. Gross margin of 60.3% expanded 50 basis points as reported and 60 basis points on a comparable basis, supported by strong volume gains, reference laboratory productivity initiatives, and net price realization, helping to offset inflationary impacts.

Operating margin was 28.9% in the quarter, 150 basis points higher than the prior year period results on a reported basis and 120 basis points on a comparable basis. Operating margin results reflect an 11% operating expense increase as reported and 10% growth on a comparable basis. Operating expense growth was driven by investments in commercial resources and higher R&D spend related to advancing the Company's innovation roadmap.

2026 Growth and Financial Performance Outlook

The Company's initial 2026 revenue guidance range of $4,632 million - $4,720 million, or reported growth of 7.6% - 9.6% and 7.0% - 9.0% on an organic basis, is supported by 8.6% - 10.6% reported and 8.0% - 10.0% organic CAG Diagnostics recurring revenue growth. The guidance range for global CAG Diagnostics recurring revenue growth reflects expectations for sustained benefits from execution drivers, supporting continued solid volume gains, and an estimated 4% full-year benefit from net price improvement. 2026 EPS guidance of $14.29 - $14.80 reflects expectations for solid organic revenue gains and a targeted 40 - 90 basis points of reported operating margin improvement.

The following table provides the Company's initial estimates for annual key financial metrics in 2026:

Amounts in millions except per share data and percentages

Growth and Financial Performance Outlook

2026

Revenue

$4,632

$4,720

Reported growth

7.6%

9.6%

Organic growth

7.0%

9.0%

CAG Diagnostics Recurring Revenue Growth

Reported growth

8.6%

10.6%

Organic growth

8.0%

10.0%

Operating Margin

32.0%

32.5%

Reported operating margin expansion

90 bps

Comparable operating margin expansion

80 bps

EPS

$14.29

$14.80

Reported growth

13%

Comparable growth

10%

14%

Other Key Metrics

Net interest expense

~ $34

Share-based compensation tax benefit

~ $15

Share-based compensation tax rate benefit

~ 1%

Effective tax rate

~ 21.3%

Share-based compensation EPS impact

~ $0.19

Reduction in average shares outstanding

Operating Cash Flow (% of Net Income)

105% - 115%

Free Cash Flow (% of Net Income)

85% - 95%

Capital Expenditures

~ $180

The following table outlines estimates of foreign currency exchange rate impacts, net of foreign currency hedging transactions, and foreign currency exchange rate assumptions reflected in the above financial performance outlook for 2026.

Estimated Foreign Currency Exchange Rate Impacts

2026

Revenue growth rate impact

~ 0.6%

CAG Diagnostics recurring revenue growth rate impact

~ 0.6%

Operating margin growth impact

~ 30 bps

EPS impact

~ $0.22

EPS growth impact

~ 2%

Go-forward Foreign Currency Exchange Rate Assumptions

In U.S. dollars

euro

$1.16

British pound

$1.33

Canadian dollar

$0.72

Australian dollar

$0.66

Relative to the U.S. dollar

Japanese yen

¥157

Chinese renminbi

¥7.05

Brazilian real

R$5.45

Conference Call and Webcast Information

IDEXX Laboratories, Inc. will host a conference call today at 8:30 a.m. (Eastern) to discuss its 2025 fourth quarter and full year financial results and management’s outlook for 2026. To participate in the conference call, dial 1-800-330-6730 or 1-213-279-1575 and reference passcode 263206. Individuals can access a live webcast of the conference call on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. (Eastern) on that day via the same link and will remain available for one year.

About IDEXX Laboratories, Inc.

IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500™ Index. Headquartered in Maine, IDEXX employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries and territories. For more information about IDEXX, visit www.idexx.com.

Note Regarding Forward-Looking Statements

This earnings release and the statements to be made in the accompanying earnings conference call contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including forward-looking statements about the Company’s business prospects and estimates of the Company’s financial results for future periods. Forward-looking statements are included under "2026 Growth and Financial Performance Outlook" and elsewhere in this earnings release and can be identified by the use of words such as "expects", "may", "anticipates", "intends", "would", "will", "plans", "believes", "estimates", "projected", "should", and similar words and expressions. Our forward-looking statements include statements relating to our expectations regarding financial and business performance; revenue growth and EPS outlooks; operating and free cash flow forecast; projected impact of foreign currency exchange rates and interest rates; projected operating margins and expenses and capital expenditures; projected tax, tax rate and EPS benefits from share-based compensation arrangements; projected effective tax rates, reduction of average shares outstanding and net interest expense; share repurchases; addition of mast cell tumor detection to IDEXX Cancer Dx panel, international launch of IDEXX Cancer Dx canine lymphoma test and canine lymphoma monitoring opportunity; IDEXX inVue Dx instrument placements, premium instrument installed base expansion and CAG instrument revenue; U.S. clinical visit levels and trends; net price realization; and impact of tariffs. These statements are intended to provide management's expectations or forecasts of future events as of the date of this earnings release; are based on management's estimates, projections, beliefs and assumptions as of the date of this earnings release; and are not guarantees of future performance. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, among other things, the adverse impact, and the duration, of macroeconomic events, conditions, and uncertainties, such as geopolitical instability (including wars, terrorist attacks, and armed conflicts), general economic uncertainty, changes in U.S. and other countries’ tariff and trade policies, severe weather and other natural conditions, and supply chain challenges on our business, results of operations, liquidity, financial condition, and stock price, as well as the other matters described under the headings "Business," "Risk Factors," "Legal Proceedings," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Quantitative and Qualitative Disclosures About Market Risk" in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and in the corresponding sections of the Company's Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025, June 30, 2025, and September 30, 2025, as well as those described from time to time in the Company’s other filings with the U.S. Securities and Exchange Commission available at www.sec.gov. The Company specifically disclaims any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Statement Regarding Non-GAAP Financial Measures

The following defines terms and conventions and provides reconciliations regarding certain measures used in this earnings release and/or the accompanying earnings conference call that are not required by, or presented in accordance with, generally accepted accounting principles in the United States of America ("GAAP"), otherwise referred to as non-GAAP financial measures. To supplement the Company’s consolidated results presented in accordance with GAAP, the Company has disclosed non-GAAP financial measures that exclude or adjust certain items. Management believes these non-GAAP financial measures provide useful supplemental information for its and investors’ evaluation of the Company’s business performance and liquidity and are useful for period-over-period comparisons of the performance of the Company’s business and its liquidity and to the performance and liquidity of our peers. While management believes that these non-GAAP financial measures are useful in evaluating the Company’s business, this information should be considered as supplemental in nature and should not be considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP. In addition, these non-GAAP financial measures may not be the same as similarly titled measures reported by other companies.

Constant currency - Constant currency references are non-GAAP financial measures which exclude the impact of changes in foreign currency exchange rates and are consistent with how management evaluates our performance and comparisons with prior and future periods. We estimated the net impacts of currency on our revenue, gross profit, operating profit, and EPS results by restating results to the average exchange rates or exchange rate assumptions for the comparative period, which includes adjusting for the estimated impacts of foreign currency hedging transactions and certain impacts on our effective tax rates. These estimated currency changes impacted fourth quarter 2025 results as follows: increased gross profit growth by 2.0%, decreased gross margin growth by 10 basis points, increased operating expense growth by 0.7%, increased operating profit margin growth by 30 basis points, and increased EPS growth by 3.4%. Estimated currency changes impacted full year 2025 results as follows: increased gross profit growth by 0.8%, decreased gross margin growth by 10 basis points, increased operating expense growth by 0.6%, negligible operating profit margin growth of 0 basis points, and increased EPS growth by 0.9%. Constant currency revenue growth represents the percentage change in revenue during the applicable period, as compared to the prior year period, excluding the impact of changes in foreign currency exchange rates. See the supplementary analysis of results below for revenue percentage change from currency for the three months and year ended December 31, 2025 and refer to the 2026 Growth and Financial Performance Outlook section of this press release for estimated foreign currency exchange rate impacts on 2026 projections and estimates.

Growth and organic revenue growth - All references to growth and organic growth refer to growth compared to the equivalent prior year period unless specifically noted. Organic revenue growth is a non-GAAP financial measure that represents the percentage change in revenue, as compared to the same period for the prior year, net of the impact of changes in foreign currency exchange rates, certain business acquisitions, and divestitures. Management believes that reporting organic revenue growth provides useful information to investors by facilitating easier comparisons of our revenue performance with prior and future periods and to the performance of our peers. Organic revenue growth should be considered in addition to, and not as a replacement of or a superior measure to, revenue growth reported in accordance with GAAP. See the supplementary analysis of results below for a reconciliation of reported revenue growth to organic revenue growth for the three and twelve months ended December 31, 2025. Please refer to the constant currency note above for a summary of foreign currency exchange rate impacts. The percentage change in revenue resulting from acquisitions represents revenues during the current year period, limited to the initial 12 months from the date of the acquisition, that are directly attributable to business acquisitions. Revenue from acquisitions is expected to increase projected full year 2026 revenue growth by an immaterial amount.

We exclude from organic revenue growth the effect of changes in foreign currency exchange rates because changes in foreign currency exchange rates are not under management’s control, are subject to volatility, and can obscure underlying business trends. We calculate the impact on revenue resulting from changes in foreign currency exchange rates by applying the difference between the weighted average exchange rates during the current year period and the comparable prior year period to foreign currency denominated revenues for the prior year period.

We also exclude from organic revenue growth the effect of certain business acquisitions and divestitures because the nature, size, and number of these transactions can vary dramatically from period to period, and because they either require or generate cash as an inherent consequence of the transaction, and therefore can also obscure underlying business and operating trends. We consider acquisitions to be a business when all three elements of inputs, processes, and outputs are present, consistent with ASU 2017-01, “Business Combinations: (Topic 805) Clarifying the Definition of a Business.” In a business combination, if substantially all the fair value of the assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets, we do not consider these assets to be a business. A typical acquisition that we do not consider a business is a customer list asset acquisition, which does not have all elements necessary to operate a business, such as employees or infrastructure. We believe the efforts required to convert and retain these acquired customers are similar in nature to our existing customer base and therefore are included in organic revenue growth.

Comparable growth metrics - Comparable gross profit growth, comparable gross margin gain (or growth), comparable operating expense growth, comparable operating profit growth and comparable operating margin gain (or growth) are non-GAAP financial measures and exclude the impact of changes in foreign currency exchange rates and non-recurring or unusual items (if any). Please refer to the constant currency note above for a summary of foreign currency exchange rate impacts. Management believes that reporting comparable gross profit growth, comparable gross margin gain (or growth), comparable operating expense growth, comparable operating profit growth and comparable operating margin gain (or growth) provides useful information to investors because it enables better period-over-period comparisons of the fundamental financial results by excluding items that vary independent of performance and provides greater transparency to investors regarding key metrics used by management. Comparable gross profit growth, comparable gross margin gain (or growth), comparable operating expense growth, comparable operating profit growth and comparable operating margin gain (or growth) should be considered in addition to, and not as replacements of or superior measures to, gross profit growth, gross margin gain, operating expense growth, operating profit growth and operating margin gain reported in accordance with GAAP.

The reconciliation of these non-GAAP financial measures is as follows:

Three Months Ended

Year-over-Year

Twelve Months Ended

Year-over-Year

December 31,

Change

December 31,

Change

Dollar amounts in thousands

2025

2024

2025

2024

Gross profit and growth (as reported)

658,114

570,660

2,659,579

2,378,927

Gross margin and margin gain

60.3

59.8

50 bps

61.8

61.0

80 bps

Less: comparability adjustments

Change from currency

11,448

—

18,110

—

Comparable gross profit and growth

646,666

570,660

2,641,470

2,378,927

Comparable gross margin and margin gain

60.4

59.8

60 bps

61.9

61.0

80 bps

Operating expenses and growth (as reported)

342,509

308,974

1,299,548

1,250,590

Less: comparability adjustments

Change from currency

2,073

—

7,897

—

Now-concluded litigation matter

—

(8,600

)

61,500

Comparable operating expense and growth

340,436

308,974

1,300,251

1,189,090

Operating profit and growth (as reported)

315,605

261,686

1,360,031

1,128,337

Operating margin and margin gain

28.9

27.4

150 bps

31.6

29.0

270 bps

Less: comparability adjustments

Change from currency

9,375

—

10,213

—

Now-concluded litigation matter

—

8,600

(61,500

)

Comparable operating profit and growth

306,230

261,686

1,341,218

1,189,837

Comparable operating margin and margin gain

28.6

27.4

120 bps

31.4

30.5

90 bps

Amounts presented may not recalculate due to rounding.

Projected 2026 comparable operating margin expansion outlined in the 2026 Growth and Financial Performance Outlook section of this earnings release reflects: (i) full year 2025 reported operating margin adjusted for 20 basis point favorable impact of discrete expense accrual related to now-concluded litigation matter in the first quarter of 2025; and (ii) projected full year 2026 reported operating margin adjusted for estimated positive year-over-year foreign currency exchange rate change impact of approximately 30 basis points.

These impacts described above reconcile reported gross profit growth, gross margin gain, operating expense growth, operating profit growth and operating margin gain (including projected 2026 operating margin expansion) to comparable gross profit growth, comparable gross margin gain, comparable operating expense growth, comparable operating profit growth and comparable operating margin gain for the Company.

Comparable EPS and growth - Comparable EPS and growth are non-GAAP financial measures that represents the percentage change in earnings per share (diluted) ("EPS") for a measurement period, as compared to the prior base period, net of the impact of changes in foreign currency exchange rates from the prior base period and excluding the tax benefits of share-based compensation activity under ASU 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, and non-recurring or unusual items (if any). Management believes comparable EPS and growth are a more useful way to measure the Company’s business performance than EPS and growth because it enables better period-over-period comparisons of the fundamental financial results by excluding items that vary independent of performance and provides greater transparency to investors regarding a key metric used by management. Comparable EPS and growth should be considered in addition to, and not as a replacement of or a superior measure to, EPS and growth reported in accordance with GAAP. Please refer to the constant currency note above for a summary of foreign currency exchange rate impacts.

The reconciliation of this non-GAAP financial measure is as follows:

Three Months Ended

Year-over-Year

Twelve Months Ended

Year-over-Year

December 31,

Growth

December 31,

Growth

2025

2024

2025

2024

Earnings per share (diluted) and growth

3.08

2.62

13.08

10.67

Less: comparability adjustments

Share-based compensation activity

0.07

0.13

0.35

0.24

Now-concluded litigation matter

—

0.08

(0.56

)

Change from currency

0.09

—

0.10

—

Comparable EPS and growth

2.92

2.49

12.55

10.99

Amounts presented may not recalculate due to rounding.

Projected 2026 comparable EPS growth outlined in the 2026 Growth and Financial Performance Outlook section of this earnings release reflects the following adjustments: (i) full year 2025 reported EPS adjusted for positive benefit of share-based compensation activity of $0.35 and $0.08 positive impact from a discrete expense accrual release related to a now-concluded litigation matter in the first quarter of 2025; and (ii) projected full year 2026 reported EPS adjusted for positive benefit of estimated share-based compensation activity of $0.19 and estimated positive year-over-year foreign currency exchange rate change impact of $0.22.

These impacts and those described in the constant currency note above reconcile reported EPS growth (including projected 2026 reported EPS growth) to comparable EPS growth for the Company.

Segment and Other Income from Operations - We report segment income from operations in our Segment Information table below. Segment income from operations is a non-GAAP financial measure that adjusts for the impact of foreign currency transaction gains and losses and should be considered in addition to, and not as a replacement for, or superior measure to, income from operations. We exclude foreign currency transaction gains and losses for each reportable segment (CAG, Water, and LPD) from segment income from operations and report the full amount of foreign currency transaction gains and losses in Other. We believe that reporting segment income from operations provides supplemental analysis to help investors further evaluate each reportable segment’s business performance by excluding foreign currency transaction gains and losses, which are centrally managed by our corporate treasury function and which we do not consider relevant for assessing the results of each reportable segment’s operations. In addition, we believe that reporting segment income from operations provides information to investors regarding key metrics that are used by management, including our chief operating decision-maker, in evaluating the performance of each reportable segment.

The reconciliation of this non-GAAP financial measure is as follows for the three and twelve months ended December 31, 2025 and 2024:

Amounts in thousands

Three Months Ended December 31,

2025

2024

Income from Operations

Impact from Foreign Currency

Segment and Other Income from Operations

Income from Operations

Impact from Foreign Currency

Segment and Other Income from Operations

CAG

291,320

1,150

292,470

236,695

3,393

240,088

Water

21,308

21,394

20,729

262

20,991

LPD

3,040

3,138

3,060

319

3,379

Other

(63

)

(1,334

)

(1,397

)

1,202

(3,974

)

(2,772

)

Total

315,605

—

315,605

261,686

—

261,686

Amounts in thousands

Twelve months ended December 31,

2025

2024

Income from Operations

Impact from Foreign Currency

Segment and Other Income from Operations

Income from Operations

Impact from Foreign Currency

Segment and Other Income from Operations

CAG

1,260,969

3,604

1,264,573

1,034,539

3,877

1,038,416

Water

92,999

269

93,268

84,244

289

84,533

LPD

2,942

287

3,229

6,272

361

6,633

Other

3,121

(4,160

)

(1,039

)

3,282

(4,527

)

(1,245

)

Total

1,360,031

—

1,360,031

1,128,337

—

1,128,337

Free cash flow - Free cash flow is a non-GAAP financial measure and means, with respect to a measurement period, the cash generated from operations during that period, reduced by the Company’s investments in property and equipment. Management believes free cash flow is a useful measure because it indicates the cash the operations of the business are generating after appropriate reinvestment for recurring investments in property and equipment that are required to operate the business. Free cash flow should be considered in addition to, and not as a replacement of or a superior measure to, net cash provided by operating activities. See the supplementary analysis of results below for our calculation of free cash flow for the years ended December 31, 2025 and 2024. To estimate projected 2026 free cash flow, we have deducted projected purchases of property and equipment (also referred to as capital expenditures) of ~180 million. Free cash flow conversion, or the net income to free cash flow ratio, is a non-GAAP financial measure that is defined as free cash flow, with respect to a measurement period, divided by net income for the same period. To calculate the free cash flow conversion for the twelve months ended December 31, 2025, we have deducted purchases of property and equipment of approximately $125 million from net cash provided from operating activities of approximately $1,182 million, divided by net income of approximately $1,059 million.

Debt to Adjusted EBITDA (Leverage Ratios) - Adjusted EBITDA, gross debt, and net debt are non-GAAP financial measures. Adjusted EBITDA is a non-GAAP financial measure of earnings before interest, taxes, depreciation, amortization, non-recurring transaction expenses incurred in connection with acquisitions, share-based compensation expense, and certain other non-cash losses and charges. Management believes that reporting Adjusted EBITDA, gross debt and net debt in the Debt to Adjusted EBITDA ratios provides supplemental analysis to help investors further evaluate the Company's business performance and available borrowing capacity under the Company's credit facility. Adjusted EBITDA, gross debt, and net debt should be considered in addition to, and not as replacements of or superior measures to, net income or total debt reported in accordance with GAAP. For further information on how Adjusted EBITDA and the Debt to Adjusted EBITDA Ratios are calculated, see the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.

After-Tax Return on Invested Capital, Excluding Cash and Investments (“ROIC”) - After-Tax Return on Invested Capital, Excluding Cash and Investments, is a non-GAAP financial measure. After-tax return on invested capital, excluding cash and investments, represents our after-tax income from operations, divided by our average invested capital, excluding cash and investments, using beginning and ending balance sheet values. Management believes that reporting ROIC provides useful information to investors for evaluating the efficiency and effectiveness of our use of capital. ROIC, after-tax income from operations and average invested capital, excluding cash and investments, are not measures of financial performance under GAAP and should be considered in addition to, and not as replacements of or superior measures to, return on assets, net income, total assets or other financial measures reported in accordance with GAAP. See the supplementary table below for reconciliation of this non-GAAP financial measure.

Notes and Definitions

Discrete litigation expense accrual - During the second quarter of 2024, the Company increased its previously established $27.5 million accrual related to a now-concluded litigation matter by $61.5 million. During the first quarter of 2025, the Company reduced this previously established $89.0 million accrual by approximately $9 million, resulting in a total accrual for this now-concluded litigation matter of approximately $80 million as of March 31, 2025, which represented our best estimate at that time of the amount of the loss.

Now-concluded litigation matter - The Company was a defendant in a litigation matter involving an alleged breach of contract for underpayment of royalty payments made from 2004 through 2017 under an expired patent license agreement, and the trial court ruled in favor of the plaintiff in 2020. Following appeals and in light of the appellate court's April 3, 2025 decision, on April 17, 2025, the Company paid the judgment of approximately $80 million, and the plaintiff executed a satisfaction and release of judgment, which was filed with the trial court on the same date, concluding this matter. For further information, see the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.

IDEXX Laboratories, Inc. and Subsidiaries

Condensed Consolidated Statement of Operations

Amounts in thousands except per share data (Unaudited)

Three Months Ended

Twelve Months Ended

December 31,

2025

2024

2025

2024

Revenue:

Revenue

1,090,579

954,288

4,303,702

3,897,504

Expenses and Income:

Cost of revenue

432,465

383,628

1,644,123

1,518,577

Gross profit

658,114

570,660

2,659,579

2,378,927

Sales and marketing

167,060

150,108

643,547

588,507

General and administrative

108,616

101,137

404,794

442,291

Research and development

66,833

57,729

251,207

219,792

Total operating expenses

342,509

308,974

1,299,548

1,250,590

Income from operations

315,605

261,686

1,360,031

1,128,337

Interest expense, net

(8,623

)

(5,299

)

(35,842

)

(18,506

)

Income before provision for income taxes

306,982

256,387

1,324,189

1,109,831

Provision for income taxes

58,794

40,238

264,725

221,964

Net Income:

Net income attributable to stockholders

248,188

216,149

1,059,464

887,867

Earnings per share: Basic

3.11

2.64

13.17

10.77

Earnings per share: Diluted

3.08

2.62

13.08

10.67

Shares outstanding: Basic

79,898

81,846

80,427

82,467

Shares outstanding: Diluted

80,480

82,538

81,025

83,246

IDEXX Laboratories, Inc. and Subsidiaries

Selected Operating Information (Unaudited)

Three Months Ended

Twelve Months Ended

December 31,

2025

2024

2025

2024

Operating Ratios

Gross profit

60.3

59.8

61.8

61.0

(as a percentage of revenue):

Sales, marketing, general and administrative expense

25.3

26.3

24.4

26.4

Research and development expense

6.1

6.0

5.8

5.6

Income from operations 1

28.9

27.4

31.6

29.0

1 Amounts presented may not recalculate due to rounding.

IDEXX Laboratories, Inc. and Subsidiaries

Segment Information

Amounts in thousands (Unaudited)

Three Months Ended

December 31,

Percent of

December 31,

Percent of

2025

Revenue

2024

Revenue

Revenue:

CAG

998,472

870,471

Water

50,530

45,153

LPD

37,485

34,557

Other

4,092

4,107

Total

1,090,579

954,288

Gross Profit:

CAG

604,293

60.5

519,412

59.7

Water

33,648

66.6

32,685

72.4

LPD

18,969

50.6

17,141

49.6

Other

1,204

29.4

1,422

34.6

Total

658,114

60.3

570,660

59.8

Income from Operations:

CAG

292,470

29.3

240,088

27.6

Water

21,394

42.3

20,991

46.5

LPD

3,138

8.4

3,379

9.8

Other

(1,397

)

(34.1

(2,772

)

(67.5

Total

315,605

28.9

261,686

27.4

Twelve Months Ended

December 31,

Percent of

December 31,

Percent of

2025

Revenue

2024

Revenue

Revenue:

CAG

3,953,285

3,574,044

Water

201,149

185,112

LPD

131,787

122,060

Other

17,481

16,288

Total

4,303,702

3,897,504

Gross Profit:

CAG

2,448,674

61.9

2,179,180

61.0

Water

139,289

69.2

130,011

70.2

LPD

64,208

48.7

62,560

51.3

Other

7,408

42.4

7,176

44.1

Total

2,659,579

61.8

2,378,927

61.0

Income from Operations:

CAG

1,264,573

32.0

1,038,416

29.1

Water

93,268

46.4

84,533

45.7

LPD

3,229

2.5

6,633

5.4

Other

(1,039

)

(5.9

(1,245

)

(7.6

Total

1,360,031

31.6

1,128,337

29.0

IDEXX Laboratories, Inc. and Subsidiaries

Revenues and Revenue Growth Analysis by Product and Service Categories and by Domestic and International Markets

Amounts in thousands (Unaudited)

Three Months Ended

Net Revenue

December 31,

2025

December 31,

2024

Dollar

Change

Reported

Revenue

Growth 1

Percentage

Change from

Currency

Percentage

Change from

Acquisitions

Organic

Revenue

Growth 1

CAG

998,472

870,471

128,001

14.7

1.9

—

12.8

United States

642,657

574,103

68,554

11.9

—

11.9

International

355,815

296,368

59,447

20.1

5.8

—

14.3

Water

50,530

45,153

5,377

11.9

2.4

—

9.5

United States

23,651

22,016

1,635

7.4

—

7.4

International

26,879

23,137

3,742

16.2

4.7

—

11.5

LPD

37,485

34,557

2,928

8.5

4.5

—

4.0

United States

7,037

6,410

627

9.8

—

9.8

International

30,448

28,147

2,301

8.2

5.4

—

2.7

Other

4,092

4,107

(15

)

(0.4

—

(0.4

Total Company

1,090,579

954,288

136,291

14.3

2.0

—

12.2

United States

675,015

603,961

71,054

11.8

—

11.8

International

415,564

350,327

65,237

18.6

5.6

—

13.0

Three Months Ended

Net CAG Revenue

December 31,

2025

December 31,

2024

Dollar

Change

Reported

Revenue

Growth 1

Percentage

Change from

Currency

Percentage

Change from

Acquisitions

Organic

Revenue

Growth 1

CAG Diagnostics recurring revenue:

849,664

757,451

92,213

12.2

1.9

—

10.2

IDEXX VetLab consumables

389,048

331,845

57,203

17.2

2.5

—

14.7

Rapid assay products

76,038

77,375

(1,337

)

(1.7

0.8

—

(2.5

Reference laboratory diagnostic and consulting services

349,248

316,027

33,221

10.5

1.6

—

8.9

CAG Diagnostics services and accessories

35,330

32,204

3,126

9.7

2.2

—

7.5

CAG Diagnostics capital – instruments

58,133

33,016

25,117

76.1

6.8

—

69.2

Veterinary software, services and diagnostic imaging systems:

90,675

80,004

10,671

13.3

0.3

—

13.0

Recurring revenue

70,603

62,898

7,705

12.2

0.4

—

11.9

Systems and hardware

20,072

17,106

2,966

17.3

0.1

—

17.2

Net CAG revenue

998,472

870,471

128,001

14.7

1.9

—

12.8

Three Months Ended

December 31,

2025

December 31,

2024

Dollar

Change

Reported

Revenue

Growth 1

Percentage

Change from

Currency

Percentage

Change from

Acquisitions

Organic

Revenue

Growth 1

CAG Diagnostics recurring revenue:

849,664

757,451

92,213

12.2

1.9

—

10.2

United States

536,672

490,240

46,432

9.5

—

9.5

International

312,992

267,211

45,781

17.1

5.6

—

11.5

1 See Statements Regarding Non-GAAP Financial Measures, above. Amounts presented may not recalculate due to rounding.

Revenues and Revenue Growth Analysis by Product and Service Categories and by Domestic and International Markets

Amounts in thousands (Unaudited)

Twelve Months Ended

Net Revenue

December 31,

2025

December 31,

2024

Dollar

Change

Reported

Revenue

Growth 1

Percentage

Change from

Currency

Percentage

Change from

Acquisitions

Organic

Revenue

Growth 1

CAG

3,953,285

3,574,044

379,241

10.6

0.8

—

9.8

United States

2,619,461

2,409,152

210,309

8.7

—

0.1

8.7

International

1,333,824

1,164,892

168,932

14.5

2.5

—

12.0

Water

201,149

185,112

16,037

8.7

0.6

—

8.0

United States

101,314

95,347

5,967

6.3

—

6.3

International

99,835

89,765

10,070

11.2

1.3

—

9.9

LPD

131,787

122,060

9,727

8.0

1.8

—

6.1

United States

25,453

22,250

3,203

14.4

—

14.4

International

106,334

99,810

6,524

6.5

2.2

—

4.3

Other

17,481

16,288

1,193

7.3

—

7.3

Total Company

4,303,702

3,897,504

406,198

10.4

0.8

—

9.6

United States

2,752,785

2,533,174

219,611

8.7

—

0.1

8.6

International

1,550,917

1,364,330

186,587

13.7

2.3

—

11.3

Twelve Months Ended

Net CAG Revenue

December 31,

2025

December 31,

2024

Dollar

Change

Reported

Revenue

Growth 1

Percentage

Change from

Currency

Percentage

Change from

Acquisitions

Organic

Revenue

Growth 1

CAG Diagnostics recurring revenue:

3,407,199

3,129,492

277,707

8.9

0.8

—

8.1

IDEXX VetLab consumables

1,496,752

1,303,250

193,502

14.8

1.1

—

13.7

Rapid assay products

348,950

359,754

(10,804

)

(3.0

0.3

—

(3.3

Reference laboratory diagnostic and consulting services

1,424,073

1,336,121

87,952

6.6

0.7

—

5.9

CAG Diagnostics services and accessories

137,424

130,367

7,057

5.4

1.0

—

4.5

CAG Diagnostics capital – instruments

200,206

131,928

68,278

51.8

2.5

—

49.3

Veterinary software, services and diagnostic imaging systems

345,880

312,624

33,256

10.6

—

0.4

10.2

Recurring revenue

276,338

250,359

25,979

10.4

—

0.4

9.9

Systems and hardware

69,542

62,265

7,277

11.7

(0.1

0.4

11.4

Net CAG revenue

3,953,285

3,574,044

379,241

10.6

0.8

—

9.8

Twelve Months Ended

December 31,

2025

December 31,

2024

Dollar

Change

Reported

Revenue

Growth 1

Percentage

Change from

Currency

Percentage

Change from

Acquisitions

Organic

Revenue

Growth 1

CAG Diagnostics recurring revenue:

3,407,199

3,129,492

277,707

8.9

0.8

—

8.1

United States

2,214,609

2,080,277

134,332

6.5

—

6.5

International

1,192,590

1,049,215

143,375

13.7

2.5

—

11.2

1 See Statements Regarding Non-GAAP Financial Measures, above. Amounts presented may not recalculate due to rounding.

Condensed Consolidated Balance Sheet

Amounts in thousands (Unaudited)

December 31,

2025

2024

Assets:

Current Assets:

Cash and cash equivalents

180,070

288,266

Accounts receivable, net

552,378

473,575

Inventories

377,756

381,877

Other current assets

303,623

256,179

Total current assets

1,413,827

1,399,897

Property and equipment, net

747,380

713,123

Other long-term assets, net

1,189,552

1,180,423

Total assets

3,350,759

3,293,443

Liabilities and Stockholders'

Equity:

Current Liabilities:

Accounts payable

110,408

114,211

Accrued liabilities

530,147

502,119

Credit facility

398,000

250,000

Current portion of long-term debt

74,995

167,787

Deferred revenue

35,264

33,799

Total current liabilities

1,148,814

1,067,916

Long-term debt, net of current portion

374,842

449,786

Other long-term liabilities, net

221,720

180,428

Total long-term liabilities

596,562

630,214

Total stockholders' equity

1,605,383

1,595,313

Total liabilities and stockholders' equity

3,350,759

3,293,443

IDEXX Laboratories, Inc. and Subsidiaries

Selected Balance Sheet Information (Unaudited)

December 31,

2025

September 30,

2025

June 30,

2025

March 31,

2025

December 31,

2024

Selected Balance Sheet Information:

Days sales outstanding 1

46.8

46.5

44.7

45.7

47.1

Inventory turns 2

1.6

1.5

1.3

1 Days sales outstanding represents the average of the accounts receivable balances at the beginning and end of each quarter divided by revenue for that quarter, the result of which is then multiplied by 91.25 days.

2 Inventory turns represent inventory-related cost of product revenue for the twelve months preceding each quarter-end divided by the average inventory balances at the beginning and end of each quarter.

IDEXX Laboratories, Inc. and Subsidiaries

Condensed Consolidated Statement of Cash Flows

Amounts in thousands (Unaudited)

Twelve Months Ended

December 31,

2025

2024

Operating:

Cash Flows from Operating Activities:

Net income

1,059,464

887,867

Non-cash charges

349,855

174,372

Changes in assets and liabilities

(227,514

)

(133,238

)

Net cash provided by operating activities

1,181,805

929,001

Investing:

Cash Flows from Investing Activities:

Purchases of property and equipment

(124,676

)

(120,922

)

Acquisitions of businesses, intangibles, and equity investment, net of cash acquired

(14,306

)

(87,698

)

Proceeds from net investment hedges

2,743

1,558

Net cash used by investing activities

(136,239

)

(207,062

)

Financing:

Cash Flows from Financing Activities:

Borrowings on credit facilities, net

148,000

—

Payments of senior debt

(178,385

)

(75,000

)

Debt issuance costs

(3,738

)

—

Repurchases of common stock

(1,216,964

)

(837,034

)

Proceeds from exercises of stock options and employee stock purchase plans

93,362

44,492

Shares withheld for statutory tax withholding payments on restricted stock

(7,239

)

(10,531

)

Net cash used by financing activities

(1,164,964

)

(878,073

)

Net effect of changes in exchange rates on cash

11,202

(9,532

)

Net change in cash and cash equivalents

(108,196

)

(165,666

)

Cash and cash equivalents, beginning of period

288,266

453,932

Cash and cash equivalents, end of period

180,070

288,266

IDEXX Laboratories, Inc. and Subsidiaries

Free Cash Flow

Amounts in thousands (Unaudited)

Twelve Months Ended

December 31,

2025

2024

Free Cash Flow:

Net cash provided by operating activities

1,181,805

929,001

Investing cash flows attributable to purchases of property and equipment

(124,676

)

(120,922

)

Free cash flow 1

1,057,129

808,079

1 See Statements Regarding Non-GAAP Financial Measures, above.

IDEXX Laboratories, Inc. and Subsidiaries

After-Tax Return on Invested Capital, Excluding Cash and Investments ("ROIC")

Amounts in thousands (Unaudited)

Numerator

For the Year Ended

December 31, 2025

Income from operations (as reported)

1,360,031

After-tax income from operations 1

1,088,141

Denominator

As of

December 31, 2025

As of

December 31, 2024

Total shareholders’ equity

1,605,383

1,595,313

Credit facility

398,000

250,000

Long-term debt, current portion

74,995

167,787

Long-term debt, net of current portion

374,842

449,786

Deferred income tax assets

(27,871

)

(125,630

)

Deferred income tax liabilities

31,865

11,312

Total invested capital

2,457,214

2,348,568

Less cash and cash equivalents

180,070

288,266

Total invested capital, excluding cash and investments

2,277,144

2,060,302

Average invested capital, excluding cash and investments 2

2,168,723

After-tax return on invested capital, excluding cash and investments

50.2

1 After-tax income from operations represents income from operations reduced by our reported effective tax rate.

2 Average invested capital, excluding cash and investments, represents the average of the amount of total invested capital, excluding cash and investments.

IDEXX Laboratories, Inc. and Subsidiaries

Common Stock Repurchases

Amounts in thousands except per share data (Unaudited)

Three Months Ended

Twelve Months Ended

December 31,

2025

2024

2025

2024

Shares repurchased in the open market

356

564

2,411

1,741

Shares acquired through employee surrender for statutory tax withholding

—

Total shares repurchased

356

564

2,427

1,760

Cost of shares repurchased in the open market

242,018

248,685

1,220,331

848,901

Cost of shares for employee surrenders

7,238

10,531

Total cost of shares

242,077

248,730

1,227,569

859,432

Average cost per share – open market repurchases

680.28

441.37

506.07

487.66

Average cost per share – employee surrenders

728.97

423.35

455.86

556.90

Average cost per share – total

680.30

441.37

505.74

488.40